Applied Therapeutics (NASDAQ:APLT) & SAB Biotherapeutics (NASDAQ:SABS) Head-To-Head Survey

SAB Biotherapeutics (NASDAQ:SABS) and Applied Therapeutics (NASDAQ:APLT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations and dividends.

Institutional and Insider Ownership

7.8% of SAB Biotherapeutics shares are held by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are held by institutional investors. 7.4% of SAB Biotherapeutics shares are held by insiders. Comparatively, 1.6% of Applied Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for SAB Biotherapeutics and Applied Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	1	1	9	0	2.73
Applied Therapeutics	1	2	0	0	1.67

SAB Biotherapeutics presently has a consensus target price of $12.00, suggesting a potential upside of 365.30%. Applied Therapeutics has a consensus target price of $1.00, suggesting a potential upside of 870.87%. Given Applied Therapeutics’ higher probable upside, analysts plainly believe Applied Therapeutics is more favorable than SAB Biotherapeutics.

Profitability

This table compares SAB Biotherapeutics and Applied Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	N/A	-6.74%	-6.06%
Applied Therapeutics	N/A	-340.84%	-175.00%

Risk and Volatility

SAB Biotherapeutics has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Comparatively, Applied Therapeutics has a beta of 2.08, meaning that its share price is 108% more volatile than the S&P 500.

Earnings and Valuation

This table compares SAB Biotherapeutics and Applied Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	$1.32 million	177.78	$13.27 million	($1.30)	-1.98
Applied Therapeutics	$1.00 million	15.86	-$105.62 million	($0.10)	-1.03

SAB Biotherapeutics has higher revenue and earnings than Applied Therapeutics. SAB Biotherapeutics is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

SAB Biotherapeutics beats Applied Therapeutics on 8 of the 13 factors compared between the two stocks.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing – human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.

About Applied Therapeutics

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.